Clinical trials recruiting for Prostatic Neoplasms, Castration-Resistant
13
Recruiting trials
29
US states with sites
26
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| New Jersey | 6 |
| California | 5 |
| Michigan | 5 |
| New York | 4 |
| Florida | 3 |
| Maryland | 3 |
| Ohio | 3 |
| Texas | 3 |
| Virginia | 3 |
| Georgia | 2 |
| Illinois | 2 |
| Louisiana | 2 |
Top cities
Los Angeles, California 4New York, New York 4Baltimore, Maryland 3Grand Rapids, Michigan 3Atlanta, Georgia 2Boston, Massachusetts 2Cincinnati, Ohio 2East Brunswick, New Jersey 2East Hanover, New Jersey 2Fairfax, Virginia 2
Self-screener
Recruiting trials
- 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
- 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
- A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.
- Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
- HTL0039732 in Participants With Advanced Solid Tumours
- Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
- Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Related conditions
Trials recruiting for Prostatic Neoplasms, Castration-Resistant often also study these conditions. Each links to its own recruiting-trial list.
Prostate cancer 1234Prostatic Neoplasms 36Metastatic Castration Resistant Prostate Cancer 67Mesothelioma, Malignant 9mCRPC (Metastatic Castration-resistant Prostate Cancer) 12Lung cancer 2180Uterine Cervical Neoplasms 5Urogenital Neoplasms 4Urinary Bladder Neoplasms 4Stomach Neoplasms 11
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Prostatic Neoplasms, Castration-Resistant trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.